Tumor Necrosis Factor-Alpha Monoclonal Antibodies for Crohns Disease: Tipping the Balance

Author(s): Silvio Danese, Nico Pagano, Erika Angelucci, Tommaso Stefanelli, Alessandro Repici, Paolo Omodei, Marco Daperno, Alberto Malesci

Journal Name: Current Medicinal Chemistry

Volume 14 , Issue 14 , 2007

Become EABM
Become Reviewer
Call for Editor


Crohns disease (CD) is a chronic inflammatory disorder which may involve any part of gastrointestinal tract. Chronic inflammation is primarily due to an immunological imbalance between pro- and anti-inflammatory cytokines, and with a defective apoptosis of lamina propria T cells. Amongst the pro-inflammatory cytokines tumor necrosis factor-α (TNF-α) seems to play a central role in pathogenesis of CD. Over the last years, increasing knowledge on the pathogenesis of CD together with progresses in bio-technology have led to the development of a number of biological agents targeting specific molecules involved in gut inflammation, most importantly TNF-α and its receptors. The aim of this paper is to critically review the rationale and state-of-the art for the use TNF-α inhibitors in the treatment of CD.

Keywords: Infliximab, TNF receptors, Lipopolysaccaride, Toll-like receptors, T lymphocytes, Certolizumab pegol

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2007
Published on: 01 March, 2012
Page: [1489 - 1497]
Pages: 9
DOI: 10.2174/092986707780831104
Price: $65

Article Metrics

PDF: 4